"Janus Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit JANUS KINASES.
| Descriptor ID |
D000075242
|
| MeSH Number(s) |
D27.505.519.389.755.500
|
| Concept/Terms |
Janus Kinase Inhibitors- Janus Kinase Inhibitors
- Inhibitors, Janus Kinase
- Kinase Inhibitors, Janus
- JAK Inhibitors
- Inhibitors, JAK
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase Inhibitors".
This graph shows the total number of publications written about "Janus Kinase Inhibitors" by people in this website by year, and whether "Janus Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 3 | 2 | 5 |
| 2021 | 0 | 2 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase Inhibitors" by people in Profiles.
-
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Multicenter Study. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2281-2291.e4.
-
Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study. Lancet Rheumatol. 2025 Jun; 7(6):e391-e402.
-
Emerging mechanisms and therapeutics in inflammatory muscle diseases. Trends Pharmacol Sci. 2025 03; 46(3):249-263.
-
JAK/STAT defects and immune dysregulation, and guiding therapeutic choices. Immunol Rev. 2024 03; 322(1):311-328.
-
How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits. Curr Rheumatol Rep. 2023 12; 25(12):295-306.
-
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases. BioDrugs. 2023 Sep; 37(5):625-635.
-
Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk. Int J Cancer. 2022 Dec 15; 151(12):2155-2160.
-
Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population. Curr Med Res Opin. 2022 08; 38(8):1431-1437.
-
Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future. N Engl J Med. 2022 01 27; 386(4):387-389.
-
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 07; 73(7):1108-1123.